KINETIC-TECHNOLOGIES
15.11.2022 07:01:41 CET | Business Wire | Press release
Power management and video/audio interface IC leader Kinetic Technologies announced two new milestone products that can increase the Power Delivery capability of USB Type-C ports to 140W, removing the barrier to expanding the range of electronic products charged via USB. The KTS1898 is dedicated to switching and protecting VBUS power, while the KTU1128 is dedicated to switching and protecting the CC1/2 and SBU1/2 lines.
The KTS1898 is a low-resistance, 5A load switch with soft-start, overvoltage, “ideal diode” reverse-current, short-circuit, over-current, over-temperature and ESD protection plus integrated surge protection of ±100V, designed to isolate and protect downstream components from abnormal VBUS voltage and current conditions. The fast reverse current protection (ideal diode) allows multiple power paths to be connected to VBUS OUT without interference.
The KTU1128 companion IC is a Thunderbolt compatible, Type-C USB data line protection and switch IC, providing low-resistance, ultra-fast OVP, and surge protection for the CC and SBU lines. Maintaining pin-to-pin compatibility with existing products, the KTU1128 increases the operating tolerance on CC and SBU lines to 32V for short-to-VBUS protection and reduces the quiescent current.
“The KTS1898 and KTU1128 are industry leading devices that allow designers to implement USB Type-C PD3.1 Extended Power Range (EPR) up to 140W and effectively address safety at the same time,” says Erik Ogren, Kinetic Technologies Senior Director of Marketing. “With the ability to withstand up to +35V on VBUS, the KTS1898 delivers the margin our customers require to build 28V systems that are designed to be safe and reliable, while the super low-resistance 25mΩ MOSFET keeps heat to a minimum, which is essential when operating at such high-power levels. The KTU1128 features the same built-in robust protection and together extends Kinetic’s lead in this application.”
KTS1898 and KTU1128 samples are available now with production starting in first quarter 2023. Visit Kinetic Technologies for further information.
Key Product Highlights:
KTS1898 – 28V VBUS Protection
-
3V to 32V Operating Voltage Range
- 35V Abs Max. Rating at IN & OUT
-
5A Continuous Current Rating
- 10A peak
- Supports 140W USB Power Delivery 3.1 (EPR)
- “Ideal Diode” Reverse-current protection with 15µs fast recovery
- Full Protection: OVP, SCP, OCP, OTP & RCP
- IEC61000-4-5 Surge Protection ±100V
- IEC61000-4-2 ESD Protection ±15kV Air, ±8kV Contact
KTU1128 – 28V CC/SBU Protection
-
2.5V to 5.5V Operating Voltage Range
- 32V DC Tolerance on CC1/2, SBU1/2
- Thunderbolt Compatible
- Fast 70ns OVP response time
- IEC61000-4-5 Surge Protection ±40V/±30V CC/SBU
- IEC61000-4-2 ESD Protection ±15kV Air, ±8kV Contact
About Kinetic Technologies
Kinetic Technologies is a global designer, developer, and provider of proprietary and innovative high-performance analog and mixed-signal semiconductor products for a wide variety of markets. Kinetic’s products help its customers efficiently regulate power, intelligently protect their devices from harmful voltage and current spikes, and deliver high-bandwidth, low-latency, and secured connectivity for video, display, and general-purpose applications.
For more information, please visit http://www.kinet-ic.com/.
*Kinetic Technologies’ logo is a trademark of Kinetic Technologies. All other brand and product names appearing in this document are the property of their respective holders.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221113005095/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom